Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 20 - 22
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s20
Publié en ligne 15 novembre 2005
  1. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996; 334 : 939–45.
  2. GISEN. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (gruppo italiano di studi epidemiologici in nefrologia). Lancet 1997; 349 : 1857–63.
  3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329 : 1456–62.
  4. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (Cooperate) : a randomised controlled trial. Lancet 2003; 361 : 117–24.
  5. Boffa JJ, Tharaux PL, Placier S, et al. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis : evidence for an endothelin-mediated mechanism. Circulation 1999; 100 : 1901–8.
  6. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice : role of endothelin. J Clin Invest 1998; 101 : 2780–9.
  7. Fakhouri F, Placier S, Ardaillou R, et al. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-beta. J Am Soc Nephrol 2001; 12 : 2701–10.
  8. Tharaux PL, Chatziantoniou C, Fakhouri F, et al. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36 : 330–6.
  9. Flamant M, Tharaux PL, Placier S et al. Epidermal growth factor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17 : 327–9.
  10. François H, Placier S, Parvez-Braun L, et al. Prevention of renal vascular and glomerular fibrosis by inhibiting tyrosine-kinase growth factor receptors. FASEB J 2004; 18 : 926–8.
  11. Fioretto P, Steffes MW, Sutherland DE, et al Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339 : 69–75.
  12. Boffa JJ, Tharaux PL, Dussaule JC, et al. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001; 37 : 490–6.
  13. Boffa JJ, Lu Y, Placier S, et al Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003; 14 : 1132–44.
  14. Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003; 14 : 2833–42.
  15. Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy : a repeat biopsy study. Am J Kidney Dis 2002; 39 : 493–502.
  16. Warnock DG. Fabry disease : diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 2005; 14 : 87–95.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.